Gapping up
News:
- SAIL +29.6% (confirms agreement to be acquired by Thoma Bravo for $6.9 bln; stockholders to receive $65.25 per share in cash)
- VERU +24.8% (Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy)
- AFMD +12.9% (Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting)
- GRCL +9.1% (to present data at AACR Annual Meeting 2022 showcasing early first-in-human results for GC502 in r/r B-ALL)
- SPPI +7% (announces that the resubmitted Biologics License Application for eflapegrastim has been accepted for filing)
- XAIR +5.5% (Beyond Cancer Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect)
- SURF +4.3% (Presents New SRF388 Data at the American Association for Cancer Research (AACR) Annual Meeting 2022)
- FSM +2% (reports Q1 production of 103,098 Gold Equivalent Ounces)
- WBX +2% (commences construction at its Arlington manufacturing facility, the company's first U.S.-based EV charger manufacturing facility)
- NRXP +1.9% (files for 7,824,727 share common stock offering by selling shareholders)
- TSVT +1.2% (bio presents new preclinical data on bbT369, an investigational dual-targeting gene-edited CAR T cell therapy, at the AACR Annual Meeting)
- AMRC +1% (provides SCE project update)
- SHOP +1% (plans 10:1 split of A and B shares, details "Founder share" aimed at making Tobi Lütke a 40% shareholder)
Analyst comments:
- CTT +1.6% (upgraded to Outperform from Neutral at Robert Baird)
- ESNT +1% (upgraded to Overweight from Neutral at JP Morgan)
- CCJ +0.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- EPAM +0.8% (upgraded to Outperform from Peer Perform at Wolfe Research)